The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Esketamine targets the glutamate neurotransmitter pathway, offering a novel mechanism for treatment-resistant depression. The treatment is available through a Risk Evaluation and Mitigation ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Ketamine-assisted therapy lifted me out of depression. But it remains costly — and controversial Health Canada approved a ...

randomized placebo-controlled trial that demonstrated “rapid and superior” improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores with esketamine nasal spray monotherapy ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ...